RNA-based next generation sequencing para la detección de fusionesProf. Fernando Lopez-Rios, Universidad CEU San Pablo, Spain
Análisis de Secuenciación Masiva automatizada mediante Genexus en tumores sólidosProf. Xavier Hernandez Losa, Vall d'Hebron University Hospital, Spain
Zukünftige therapierelevante Veränderungen per NGS in nur einem TagProf. Michael Hummel, Charité CCC, Germany
The use of Genexus system and Oncomine™ Precision Assay as fast and sensitive NGS solution for solid tumour molecular characterisationDr. Hana Lango Allen, East Genomic Laboratory Hub, UK
Verification of next generation sequencing in the pathology department Cork University HospitalDr. Reiltin Werner, Cork University Hospital, Ireland
Utilizzo del Genexus per la profilazione molecorare dei tumori in NGSDr. Annarita Destro, Humanitas Research Hospital, Italy
The economic advantage of 1-day NGSDr. Javier Hernandez Losa, Director of Molecular Biology Laboratory, Pathology Department, Vall d'Hebron University Hospital, Spain
Pivoting from Cancer to COVID-19 in a global pandemicDr. Paul Hofman, MD, PhD, Laboratory of Clinical and Experimental Pathology, Louis Pasteur Hospital, Nice, France
Visión del Oncólogo de la Medicina de PrecisiónProf. Mariano Provencio, Hospital Universitario Puerta de Hierro, Spain
Precision Medicine: Oncologist perspective on the impact of the molecular evaluation of solid tumourProf. Mariano Provencio, Hospital Universitario Puerta de Hierro, Spain
Il paradigma in evoluzione della medicina di precisione nel cancro del polmone La prospettiva dell'oncologoDr. Francesco Passiglia, University of Turin, Italy
Ricadute pratiche della caratterizzazione molecolare multigenica in oncologiaDr. Carlo Genova, Ospedale Policlinico San Martino, Italy
Selpercatinib – der erste zugelassene spezifische RET-Inhibitor im EinsatzDr. Damian Rieke, Charité – Universitätsmedizin Berlin, Germany
Estudio molecular del cáncer de pulmón: De los métodos convencionales a la NGSDr. Yolanda Ruano Dominguez, Hospital 12 de Octubre, Spain
Clinical research on genomic profiling using the Oncomine™ Comprehensive Assay PlusDr. Ines Raineri, Institute for Pathology Medica AG, Switzerland
Homologous Recombination Repair Deficiency HRDDr. Andreas Jung, University of Munich, Germany
RET als Tumormarker beim NSCLC und SchilddrüsenkarzinomProf. Dr. Peter Wild, Universitätsklinikum Frankfurt, Germany
Multicentric study to evaluateDr. Massimo Barberis, Istituto Europeo di Oncologia, Italy
The role of comprehensive genomic profiling in emerging biomarker testingDr. Nicola Normanno, Director of Department of Experimental Oncology, INT-Fondazione Pascale, Naples, Italy
Algorithms to use different sizes of panels for different types of cancer samples - experience in a molecular pathology labProf. Dr. Peter Wild, Director of Dr. Senckenberg Institute for Pathology, University Hospital Frankfurt, Germany
Introduction to multi-biomarker profiling: what is the data saying about it?Dr. Jose Luis Costa, EMEA Medical Affairs Director,
Thermo Fisher Scientific
Multicentric study to evaluate in-house solution for CGPDr. Massimo Barberis, Director of Histopathology and Molecular Diagnostics Unit, European Institute of Oncology, Italy
Comprehensive genomic profiling with the Oncomine Comprehensive Assay PlusIlaria Alborelli, PhD, Clinical Data Analyst, Institute of Pathology and Medical Genetics, University Hospital Basel, Switzerland
